Side effects of propionyl‐L‐carnitine regimen · intermittent claudication
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Side effects of propionyl‐L‐carnitine regimen · intermittent claudication
1 finding from 1 review
Reaction time (8 lamps) · healthy young women
1 finding from 1 review
Vigilance · healthy young women
1 finding from 1 review
Immediate memory · healthy young women
1 finding from 1 review
Delayed memory · healthy young women
1 finding from 1 review
Adverse effects ‐ not reported · healthy young women
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Progression of disease (to Fontaine stage III or IV or necessity for intervention (endovascular or surgery)) · intermittent claudication
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ankle brachial index · intermittent claudication
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Absolute claudication distance (in meters) · intermittent claudication
1 finding from 1 review
Initial claudication distance (in meters) · intermittent claudication
1 finding from 1 review
Quality of life · intermittent claudication
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain at 6 months or more; all doses Assessed by change from baseline, using a 0‐ to 100‐mm VAS, where higher scores indicate more pain) · people with diabetic peripheral neuropathy
1 finding from 1 review
Impairment of sensation Assessed by quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more · the treatment of diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptom quality and severity Assessed by NSS score (range of possible scores 0 to 9; higher scores indicate more symptoms) · the treatment of diabetic peripheral neuropathy
1 finding from 1 review
Adverse events · the treatment of diabetic peripheral neuropathy
Acetyl‐L‐carnitine showed no clear difference in adverse events compared with methylcobalamin (low certainty).
1 finding from 1 review
Functional impairment and disability Assessed by NIS or NDS at 6 months or more · people with diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Impairment of sensation Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more · people with diabetic peripheral neuropathy
1 finding from 1 review
Impairment of sensation Assessed by quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more · people with diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptom quality and severity Assessed by change in symptom score on a validated screening questionnaire (NSS or MNSI) at 6 months or more · people with diabetic peripheral neuropathy
1 finding from 1 review
no estimate extracted
2 participants
GRADE not reported